Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Analysis of Profitability Ratios 
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Allergan PLC, profitability ratios (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Return on Sales
Gross profit margin 83.73% 84.50% 84.96% 85.09% 86.21% 86.12% 86.39% 86.56% 86.03% 86.40% 86.65% 87.11% 87.56% 87.23% 86.55% 81.36% 73.17% 68.08%
Operating profit margin -21.34% -27.63% -60.39% -55.48% -50.30% -39.57% -5.95% -32.39% -35.34% -37.15% -43.48% -19.74% -17.36% -12.53% -13.13% -20.47% -15.77% -20.00%
Net profit margin -15.44% -32.76% -58.50% -54.25% -45.94% -32.28% 14.50% -9.86% -11.51% -25.88% -46.82% 79.17% 82.42% 102.76% 107.27% 31.97% 29.44% 25.98%
Return on Investment
Return on equity (ROE) -4.28% -9.06% -15.82% -14.25% -11.73% -7.83% 3.30% -2.24% -2.55% -5.59% -10.18% 15.86% 16.16% 19.65% 15.99% 5.77% 6.05% 5.11%
Return on assets (ROA) -2.81% -5.57% -9.80% -8.91% -7.36% -5.01% 2.18% -1.46% -1.65% -3.49% -6.09% 9.56% 9.58% 11.61% 9.99% 3.34% 3.44% 2.88%

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Allergan PLC gross profit margin ratio deteriorated from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Allergan PLC operating profit margin ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Allergan PLC net profit margin ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Allergan PLC ROE improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
ROA A profitability ratio calculated as net income divided by total assets. Allergan PLC ROA improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.

Gross Profit Margin

Allergan PLC, gross profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Gross profit 2,981,300 3,647,000 3,411,700 3,437,800 3,099,300 3,489,700 3,314,600 3,642,400 3,149,300 3,745,200 3,447,800 3,457,200 3,122,500 3,384,600 3,160,000 3,243,300 2,921,900 2,247,200 2,846,000 3,624,900 1,542,500
Net revenues 3,604,400 4,351,000 4,050,700 4,090,100 3,597,100 4,079,700 3,911,400 4,124,200 3,672,100 4,326,100 4,034,300 4,007,400 3,572,900 3,864,300 3,622,200 3,684,800 3,399,300 2,664,500 4,088,900 5,755,000 2,562,600
Profitability Ratio
Gross profit margin1 83.73% 84.50% 84.96% 85.09% 86.21% 86.12% 86.39% 86.56% 86.03% 86.40% 86.65% 87.11% 87.56% 87.23% 86.55% 81.36% 73.17% 68.08%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 77.43% 77.64%
Amgen Inc. 78.90% 80.38%
Bristol-Myers Squibb Co. 68.02% 69.10%
Eli Lilly & Co. 79.22% 78.85%
Gilead Sciences Inc. 79.06% 78.86%
Johnson & Johnson 66.15% 66.42%
Merck & Co. Inc. 70.11% 69.87%
Pfizer Inc. 80.03% 80.25%
Regeneron Pharmaceuticals Inc. 89.72% 90.05%
Thermo Fisher Scientific Inc. 44.30% 44.35%
Vertex Pharmaceuticals Inc. 87.24% 86.84%

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Gross profit margin = 100 × (Gross profitQ1 2020 + Gross profitQ4 2019 + Gross profitQ3 2019 + Gross profitQ2 2019) ÷ (Net revenuesQ1 2020 + Net revenuesQ4 2019 + Net revenuesQ3 2019 + Net revenuesQ2 2019)
= 100 × (2,981,300 + 3,647,000 + 3,411,700 + 3,437,800) ÷ (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100) = 83.73%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Allergan PLC gross profit margin ratio deteriorated from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.

Operating Profit Margin

Allergan PLC, operating profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Operating income (loss) (1,299,600) (276,600) (596,600) (1,262,900) (2,309,200) (5,384,100) 257,500 (467,000) (654,000) (90,500) (4,022,300) (902,400) (906,000) (900,000) (266,400) (487,600) (171,500) (830,400) (1,343,500) (162,900) (677,700)
Net revenues 3,604,400 4,351,000 4,050,700 4,090,100 3,597,100 4,079,700 3,911,400 4,124,200 3,672,100 4,326,100 4,034,300 4,007,400 3,572,900 3,864,300 3,622,200 3,684,800 3,399,300 2,664,500 4,088,900 5,755,000 2,562,600
Profitability Ratio
Operating profit margin1 -21.34% -27.63% -60.39% -55.48% -50.30% -39.57% -5.95% -32.39% -35.34% -37.15% -43.48% -19.74% -17.36% -12.53% -13.13% -20.47% -15.77% -20.00%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 39.86% 39.03%
Amgen Inc. 41.89% 43.57%
Bristol-Myers Squibb Co. 16.30% 22.62%
Eli Lilly & Co. 25.64% 22.29%
Gilead Sciences Inc. 19.89% 19.38%
Johnson & Johnson 25.62% 24.15%
Merck & Co. Inc. 25.49% 24.77%
Pfizer Inc. 24.20% 25.46%
Regeneron Pharmaceuticals Inc. 30.45% 28.10%
Thermo Fisher Scientific Inc. 17.86% 17.99%
Vertex Pharmaceuticals Inc. 34.05% 28.77%

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Operating profit margin = 100 × (Operating income (loss)Q1 2020 + Operating income (loss)Q4 2019 + Operating income (loss)Q3 2019 + Operating income (loss)Q2 2019) ÷ (Net revenuesQ1 2020 + Net revenuesQ4 2019 + Net revenuesQ3 2019 + Net revenuesQ2 2019)
= 100 × (-1,299,600 + -276,600 + -596,600 + -1,262,900) ÷ (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100) = -21.34%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Allergan PLC operating profit margin ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.

Net Profit Margin

Allergan PLC, net profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Net income (loss) attributable to shareholders 378,000 (317,200) (786,800) (1,759,000) (2,408,000) (4,299,900) (37,900) (472,500) (286,100) 3,121,300 (3,955,700) (725,900) (2,565,200) (600) 15,220,000 (501,700) 255,700 (630,900) 5,301,200 (243,100) (512,000)
Net revenues 3,604,400 4,351,000 4,050,700 4,090,100 3,597,100 4,079,700 3,911,400 4,124,200 3,672,100 4,326,100 4,034,300 4,007,400 3,572,900 3,864,300 3,622,200 3,684,800 3,399,300 2,664,500 4,088,900 5,755,000 2,562,600
Profitability Ratio
Net profit margin1 -15.44% -32.76% -58.50% -54.25% -45.94% -32.28% 14.50% -9.86% -11.51% -25.88% -46.82% 79.17% 82.42% 102.76% 107.27% 31.97% 29.44% 25.98%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 24.77% 23.69%
Amgen Inc. 33.64% 35.32%
Bristol-Myers Squibb Co. 3.08% 13.15%
Eli Lilly & Co. 23.97% 37.27%
Gilead Sciences Inc. 22.17% 24.35%
Johnson & Johnson 20.75% 18.42%
Merck & Co. Inc. 21.10% 21.01%
Pfizer Inc. 32.32% 31.45%
Regeneron Pharmaceuticals Inc. 28.56% 26.91%
Thermo Fisher Scientific Inc. 14.31% 14.47%
Vertex Pharmaceuticals Inc. 31.35% 28.27%

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Net profit margin = 100 × (Net income (loss) attributable to shareholdersQ1 2020 + Net income (loss) attributable to shareholdersQ4 2019 + Net income (loss) attributable to shareholdersQ3 2019 + Net income (loss) attributable to shareholdersQ2 2019) ÷ (Net revenuesQ1 2020 + Net revenuesQ4 2019 + Net revenuesQ3 2019 + Net revenuesQ2 2019)
= 100 × (378,000 + -317,200 + -786,800 + -1,759,000) ÷ (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100) = -15.44%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Allergan PLC net profit margin ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.

Return on Equity (ROE)

Allergan PLC, ROE calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Net income (loss) attributable to shareholders 378,000 (317,200) (786,800) (1,759,000) (2,408,000) (4,299,900) (37,900) (472,500) (286,100) 3,121,300 (3,955,700) (725,900) (2,565,200) (600) 15,220,000 (501,700) 255,700 (630,900) 5,301,200 (243,100) (512,000)
Shareholders’ equity 57,997,700 58,173,600 58,475,200 59,674,700 61,542,000 65,114,100 70,507,800 71,243,500 72,327,900 73,821,100 71,159,400 75,220,400 75,188,400 76,192,700 89,725,900 76,643,900 77,450,000 76,591,400 77,473,700 72,069,100 71,404,800
Profitability Ratio
ROE1 -4.28% -9.06% -15.82% -14.25% -11.73% -7.83% 3.30% -2.24% -2.55% -5.59% -10.18% 15.86% 16.16% 19.65% 15.99% 5.77% 6.05% 5.11%
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc. 80.92% 81.07%
Bristol-Myers Squibb Co. 1.91% 6.66%
Eli Lilly & Co. 179.72% 319.09%
Gilead Sciences Inc. 22.49% 23.91%
Johnson & Johnson 28.01% 25.42%
Merck & Co. Inc. 38.72% 37.99%
Pfizer Inc. 24.21% 25.77%
Regeneron Pharmaceuticals Inc. 18.79% 19.08%
Thermo Fisher Scientific Inc. 12.85% 12.45%
Vertex Pharmaceuticals Inc. 23.38% 19.34%

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
ROE = 100 × (Net income (loss) attributable to shareholdersQ1 2020 + Net income (loss) attributable to shareholdersQ4 2019 + Net income (loss) attributable to shareholdersQ3 2019 + Net income (loss) attributable to shareholdersQ2 2019) ÷ Shareholders’ equity
= 100 × (378,000 + -317,200 + -786,800 + -1,759,000) ÷ 57,997,700 = -4.28%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Allergan PLC ROE improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.

Return on Assets (ROA)

Allergan PLC, ROA calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Net income (loss) attributable to shareholders 378,000 (317,200) (786,800) (1,759,000) (2,408,000) (4,299,900) (37,900) (472,500) (286,100) 3,121,300 (3,955,700) (725,900) (2,565,200) (600) 15,220,000 (501,700) 255,700 (630,900) 5,301,200 (243,100) (512,000)
Total assets 88,426,200 94,699,100 94,408,900 95,480,700 98,036,300 101,787,600 106,542,500 108,858,800 112,021,300 118,341,900 118,992,800 124,734,800 126,836,900 128,986,300 143,607,700 132,619,100 136,073,700 135,840,700 142,816,300 138,411,100 139,460,700
Profitability Ratio
ROA1 -2.81% -5.57% -9.80% -8.91% -7.36% -5.01% 2.18% -1.46% -1.65% -3.49% -6.09% 9.56% 9.58% 11.61% 9.99% 3.34% 3.44% 2.88%
Benchmarks
ROA, Competitors2
AbbVie Inc. 9.25% 8.84%
Amgen Inc. 12.45% 13.13%
Bristol-Myers Squibb Co. 0.74% 2.65%
Eli Lilly & Co. 13.46% 21.17%
Gilead Sciences Inc. 8.31% 8.74%
Johnson & Johnson 11.07% 9.59%
Merck & Co. Inc. 11.95% 11.66%
Pfizer Inc. 9.47% 9.72%
Regeneron Pharmaceuticals Inc. 14.46% 14.29%
Thermo Fisher Scientific Inc. 6.25% 6.33%
Vertex Pharmaceuticals Inc. 16.99% 14.15%

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
ROA = 100 × (Net income (loss) attributable to shareholdersQ1 2020 + Net income (loss) attributable to shareholdersQ4 2019 + Net income (loss) attributable to shareholdersQ3 2019 + Net income (loss) attributable to shareholdersQ2 2019) ÷ Total assets
= 100 × (378,000 + -317,200 + -786,800 + -1,759,000) ÷ 88,426,200 = -2.81%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Allergan PLC ROA improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.